Nonrandomized registries for de novo lesions (FIM) and in-stent restenosis
In. Serruys, Patrick W; Gershilick, Anthony H. Handbook of drug-eluting stents. New York, Taylor & Francis, 2005. p.103-107, ilus, tab, graf.
Monografía
en Inglés
| LILACS, SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1069447
ABSTRACT
Takind advantage of the knowledge accumulated over decades of unsuccessful attempts to prevent restenosis, novel devices for local drug-eluting stents, have been developed in the recent years. Sirolimus eluting Bx Velocity stents is certainly one of these novel technologies that may finnally represent the "magic bullet" we have been searching for in our war against the restenosis. The first clinical evaluation of this new technology was initiated in December 1999. This endeavor was conducted at Institute Dante Pazzanese of Cardiology in São Paulo, Braziland at Thoraxcenter, Rotterdam, The Netherlands. The unparalleled 1-year out-come of this first series of patients treated with sirulimus-eluting stents (SES) paved the way to launch a more challenging pilot study involving only patients with in-stent restenosis, which was started in 2000...
Buscar en Google
Índice:
LILACS (Américas)
Asunto principal:
Stents
/
Reestenosis Coronaria
/
Lesiones Cardíacas
Tipo de estudio:
Ensayo Clínico Controlado
Límite:
Humanos
Idioma:
Inglés
Año:
2005
Tipo del documento:
Monografía
Institución/País de afiliación:
Instituto Dante Pazzanese de Cardiologia/BR
Similares
MEDLINE
...
LILACS
LIS